NCT07906158Befejeződött

PET/CT-Based Intratumoral Heterogeneity and Multimodal Imaging for Tumor Diagnosis and Prognosis

Application of 18F-FDG PET/CT Multimodal Metabolic-Anatomical Features and Intratumoral Heterogeneity in Tumor Diagnosis, Staging, and First-Line Therapy Prognostic Stratification: A Multicenter Retrospective and Prospective Cohort Study

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. okt. 30.

Rövid összefoglaló (regiszter, angolul)

Background \& Rationale: Intratumoral heterogeneity (ITH) is a recognized hallmark and critical driver of therapeutic resistance, rapid disease progression, and poor survival across solid malignancies, notably advanced non-small-cell lung cancer (NSCLC). While tissue biopsies provide histopathologic confirmation, they are invasive and subject to severe spatial sampling bias. Standard whole-tumor radiomics from single-modality CT often masks localized subregional ecological niches. 18F-FDG PET/CT unites glucose metabolic activity with anatomical resolution, offering an ideal non-invasive tool to map whole-tumor spatial and functional heterogeneity in vivo. Methods \& Design: In this multicenter, bidirectional (retrospective and prospective) observational cohort study, 900 advanced NSCLC patients receiving first-line systemic therapies (chemotherapy, anti-PD-1 immunotherapy, and EGFR-TKIs) were enrolled. Baseline 18F-FDG PET/CT scans obtained within 2 weeks prior to therapy were partitioned into distinct biological habitats using entropy-intensity clustering. IBSI-compliant radiomic features were extracted to develop treatment-specific imaging intratumoral heterogeneity (IITH) signatures. Diagnostic accuracy for staging/metastases and prognostic performance for 6-month progression status, progression-free survival (PFS), and overall survival (OS) were comprehensively validated across internal, external multicenter, and independent prospective cohorts, with biological explainability benchmarked against digital histopathology (HoVer-Net nuclear morphometrics) and transcriptomics.

Állapot (regiszter): Befejeződött
Vizsgálattípus: Megfigyeléses
Résztvevők száma: 900 (tényleges)
Első benyújtás: 2026. okt. 22.
Kezdés: 2019. febr. 1.
Elsődleges befejezés: 2023. dec. 31.
Fő szponzor: Shengjing Hospital
Betegségek: Tüdőrák
NCT-szám: NCT07906158

Mit vállalsz

Vizsgálat típusa: Megfigyeléses
Bevont résztvevők: 900
2019. febr. 1. és az elsődleges befejezés (2023. dec. 31.) között
1 helyszín, 1 országban
Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

Unclear pathological diagnosis, non-primary malignant tumor, or concomitant active second primary malignant tumor at other sites;
Prior surgical resection, radical radiotherapy, or systemic anti-tumor therapy (neoadjuvant therapy, conversion therapy, etc.) targeting the primary lesion before baseline PET/CT examination;

Más betegség

Incomplete PET/CT imaging data, contrast medium injection failure, extremely low image signal-to-noise ratio, or severe respiratory motion artifacts/intracorporeal metal implant artifacts which prevent accurate lesion delineation and radiomic analysis;

Laborértékek

Severe uncontrolled systemic metabolic diseases (e.g., severe diabetes with fasting blood glucose \> 11.1 mmol/L that significantly interferes with 18F-FDG uptake distribution), severe hepatic or renal insufficiency, or severe infection that renders the patient intolerant to examination and follow-up;

Egyéb

Severe missing of key clinical follow-up data, loss to follow-up, or inability to accurately determine objective treatment response and survival endpoints.

Kiket keres a vizsgálat

Aged 18-79 years, male or female;
Confirmed primary solid malignant tumor (non-small cell lung cancer) by histopathological or cytological examination, clinically staged as stage III-IV according to the 8th edition of AJCC/UICC staging system;
Planned to receive or receiving first-line standard systemic therapy (including chemotherapy, anti-PD-1/PD-L1 immune checkpoint inhibitors, or EGFR-TKI targeted therapy);
Standardized baseline 18F-FDG PET/CT examination completed within 2 weeks before the first anti-tumor treatment, with complete whole-body/thoracic metabolic parameters (SUVmax, MTV, etc.) and thin-slice enhanced/non-enhanced CT image sequences; images with satisfactory quality and without severe respiratory motion artifacts;
At least one measurable solid tumor target lesion per RECIST v1.1;
Complete baseline clinicopathological characteristics, baseline laboratory data, and standardized long-term follow-up records (including progression-free survival and overall survival status);
Written informed consent signed by the patient or legal representative (waiver of informed consent for the retrospective part has been approved by the institutional review board).

Életkor a regiszterben: 18 év – 79 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

Helyszín	Város	Ország	Helyszín állapota
Shengjing Hospital affiliated to China Medical University Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát	Shenyang	Kína	Ismeretlen állapot

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.